Adial Pharmaceuticals, Inc.ADIL

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · adial.com

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for addiction and related disorders. Its lead candidate AD04 is a genetically targeted serotonin-3 antagonist for alcohol use disorder in patients with selected genotypes.

Key ratios

ROA

-40.0%TTM

2025 -83.2%2024 -105.9%2023 -82.2%

ROE

-2011.6%TTM

2025 -170.7%2024 -323.8%2023 -190.3%

Recent news

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) 2026-08-25 · GlobeNewswire

Track ADIL in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer